We found that XPO1 inhibition with the FDA-approved inhibitor selinexor synergized with the eIF4A inhibitor rocaglamide to suppress NB cell growth in vitro (Supplementary Fig. S9D–F). This evidence concerns the gene XPO1 and neuroblastoma.